MB

Matthew Bloom

Venture Investor | Entrepreneur | Startup Advisor

New Haven, Connecticut

Invests in

Stages:

Locations:

  • Min Investment:

    $150,000.00
  • Max Investment:

    $7,000,000.00
  • Target Investment:

    $3,500,000.00

Skills

Financial Modeling
Capital Budgeting
Venture Capital
Valuation
Due Diligence
Lifesciences
Start-ups
DCF
Investments
Business Valuation
Medical Devices
Data Analysis
Business Strategy
Competitive Analysis
Financial Analysis
Corporate Finance
Strategy
Mergers & Acquisitions
Market Research
Business Development

Work Experience

  • Managing Director, Investments

    2021 - 2022

    CI is consistently ranked as one of the top 25 most active seed/early-stage VC firms in the US by Pitchbook & CB Insights. Investments led at CI: 1Touch.io, Acadian Ventures, Continuity (Acquired by Mitratech), Copyleaks, EyeControl, ReRent, SecBI (Acquired by LogPoint), Service Insight, Shelf.io, Shoplandia, Slooh, Synergio and Zorus Tech. Previous successful investments supported: CyVek ( Acquired by Bio-Techne Corp.; NASDAQ: TECH), PCC Technologies (Acquired by Clearview Capital), iDevices (Acquired by Hubbell Inc.; NYSE: HUBB), Tru Optik (Acquired by TransUnion; NYSE: TRU), and Payveris (Acquired by Paymentus; NYSE: PAY).

  • Director, Investments

    2017 - 2021

  • Senior Investment Associate

    2016 - 2017

  • Investment Associate

    2014 - 2016

2020 - 2022

  • Board Member

    2020 - 2022

2017 - 2022

  • Board Member

    2017 - 2022

2017 - 2022

  • Board Member

    2017 - 2022

  • Board Member

    2021 - 2021

  • Board Member

    2016 - 2021

2018 - 2020

  • Board Member

    2018 - 2020

  • Senior Venture Analyst

    2012 - 2014

    Excell is a seed VC firm investing in high-tech ventures primarily across the greater Western and Upstate NY regions.

Creative Bioreactor Designs, Inc.

2009 - 2011

  • Co-Founder & Business Development Manager

    2009 - 2011

    Creative Bioreactor Design Inc. is a start-up biomedical company focused on accelerating the growth of the regenerative medicine industry by developing and delivering innovative equipment and systems for engineered tissues and organs.